Bivalirudin resulted in an average drug acquisition cost savings of $402 per patient (as treated) compared with UFH plus glycoprotein IIb/IIIa inhibitors. Treatment with bivalirudin also resulted ...

The chemistry and pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing and administration, and pharmacoeconomics of bivalirudin are reviewed; clinical ...